American Heart Journal
Volume 158, Issue 4 , Pages 637-643 , October 2009

Drug-eluting versus bare-metal stents for treating saphenous vein grafts

  • Mehdi H. Shishehbor, DO, MPH

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
    • ,
  • Riem Hawi, MD

      Affiliations

    • Department of Internal Medicine, Cleveland Clinic, Cleveland, OH
    • ,
  • Inder M. Singh, MD, MS

      Affiliations

    • Division of Cardiovascular Medicine, Indiana University School of Medicine, Indianapolis, IN
    • ,
  • E. Murat Tuzcu, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
    • ,
  • Deepak L. Bhatt, MD, MPH

      Affiliations

    • Veterans Affairs Boston Healthcare System and Brigham and Women's Hospital, Boston, MA
    • ,
  • Stephen G. Ellis, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
    • ,
  • Samir R. Kapadia, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
    • Corresponding Author InformationReprint requests: Samir R. Kapadia, MD, 9500 Euclid Ave, F-25, Cleveland Clinic, Cleveland, OH 44114.

Received 9 May 2009 ,Accepted 6 August 2009.

References 

  1. King SB, Smith SC, Hirshfeld JW, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol. 2008;51:172–209
  2. Baim DS. Percutaneous treatment of saphenous vein graft disease: the ongoing challenge. J Am Coll Cardiol. 2003;42:1370–1372
  3. de Feyter PJ. Percutaneous treatment of saphenous vein bypass graft obstructions: a continuing obstinate problem. Circulation. 2003;107:2284–2286
  4. Brilakis ES, Saeed B, Banerjee S. Use of drug-eluting stents in saphenous vein aortocoronary bypass graft lesions: a critical appraisal. J Interv Cardiol. 2008;21:151–157
  5. Vermeersch P, Agostoni P, Verheye S, et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol. 2006;48:2423–2431
  6. Vermeersch P, Agostoni P, Verheye S, et al. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol. 2007;50:261–267
  7. Brilakis ES, Lichtenwalter C, de Lemos JA, et al. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol. 2009;53:919–928
  8. Blankenship JC. Parsing the subsets: when small studies create confusion. Catheter Cardiovasc Interv. 2008;72:23–24
  9. Colombo A, Chieffo A. Drug-eluting stent update 2007: part III: technique and unapproved/unsettled indications (left main, bifurcations, chronic total occlusions, small vessels and long lesions, saphenous vein grafts, acute myocardial infarctions, and multivessel disease). Circulation. 2007;116:1424–1432
  10. Morrison DA, Sethi G, Sacks J, et al. Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia: AWESOME randomized trial and registry experience with post-CABG patients. J Am Coll Cardiol. 2002;40:1951–1954
  11. Savage MP, Douglas JS, Fischman DL, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med. 1997;337:740–747
  12. Brilakis ES, Berger PB. Should bare metal or drug-eluting stents be used during PCI of saphenous vein graft lesions: waiting for Godot?. Catheter Cardiovasc Interv. 2008;72:815–818
  13. Hanekamp CE, Koolen JJ, Den Heijer P, et al. Randomized study to compare balloon angioplasty and elective stent implantation in venous bypass grafts: the Venestent study. Catheter Cardiovasc Interv. 2003;60:452–457
  14. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009–1019
  15. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584–2591
  16. Jeger RV, Schneiter S, Kaiser C, et al. Drug-eluting stents compared with bare metal stents improve late outcome after saphenous vein graft but not after large native vessel interventions. Cardiology. 2009;112:49–55
  17. Assali A, Raz Y, Vaknin-Assa H, et al. Beneficial 2-years results of drug-eluting stents in saphenous vein graft lesions. EuroIntervention. 2008;4:108–114
  18. Kaplan S, Barlis P, Kiris A, et al. Immediate procedural and long-term clinical outcomes following drug-eluting stent implantation to ostial saphenous vein graft lesions. Acute Card Care. 2008;10:88–92
  19. Minutello RM, Bhagan S, Sharma A, et al. Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease. J Interv Cardiol. 2007;20:458–465
  20. Hoffmann R, Pohl T, Koster R, et al. Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study. Heart. 2007;93:331–334
  21. Wohrle J, Nusser T, Kestler HA, et al. Comparison of the slow-release polymer-based paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions. Clin Res Cardiol. 2007;96:70–76
  22. Lee MS, Shah AP, Aragon J, et al. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv. 2005;66:507–511
  23. Ge L, Iakovou I, Sangiorgi GM, et al. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J Am Coll Cardiol. 2005;45:989–994
  24. Lozano I, Garcia-Camarero T, Carrillo P, et al. Comparison of drug-eluting and bare metal stents in saphenous vein grafts. Immediate and long-term results. Rev Esp Cardiol. 2009;62:39–47
  25. van Twisk PH, Daemen J, Kukreja N, et al. Four-year safety and efficacy of the unrestricted use of sirolimus- and paclitaxel-eluting stents in coronary artery bypass grafts. EuroIntervention. 2008;4:311–317
  26. Okabe T, Lindsay J, Buch AN, et al. Drug-eluting stents versus bare metal stents for narrowing in saphenous vein grafts. Am J Cardiol. 2008;102:530–534
  27. Gioia G, Benassi A, Mohendra R, et al. Lack of clinical long-term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts. Catheter Cardiovasc Interv. 2008;72:13–20
  28. Applegate RJ, Sacrinty M, Kutcher M, et al. Late outcomes of drug-eluting versus bare metal stents in saphenous vein grafts: propensity score analysis. Catheter Cardiovasc Interv. 2008;72:7–12
  29. Ramana RK, Ronan A, Cohoon K, et al. Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease. Catheter Cardiovasc Interv. 2008;71:886–893
  30. Vignali L, Saia F, Manari A, et al. Long-term outcomes with drug-eluting stents versus bare metal stents in the treatment of saphenous vein graft disease (results from the REgistro Regionale AngiopLastiche Emilia-Romagna registry). Am J Cardiol. 2008;101:947–952
  31. Bansal D, Muppidi R, Singla S, et al. Percutaneous intervention on the saphenous vein bypass grafts—long-term outcomes. Catheter Cardiovasc Interv. 2008;71:58–61
  32. Ellis SG, Kandzari D, Kereiakes DJ, et al. Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study. J Invasive Cardiol. 2007;19:404–409
  33. Chu WW, Rha SW, Kuchulakanti PK, et al. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol. 2006;97:34–37
  34. Holmes DR, Kereiakes DJ, Laskey WK, et al. Thrombosis and drug-eluting stents: an objective appraisal. J Am Coll Cardiol. 2007;50:109–118
  35. Christiansen JF, Hartwig D, Bechtel JF, et al. Diseased vein grafts express elevated inflammatory cytokine levels compared with atherosclerotic coronary arteries. Ann Thorac Surg. 2004;77:1575–1579
  36. Ellis SG, Brener SJ, DeLuca S, et al. Late myocardial ischemic events after saphenous vein graft intervention—importance of initially “nonsignificant” vein graft lesions. Am J Cardiol. 1997;79:1460–1464
  37. Keeley EC, Velez CA, O'Neill WW, et al. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts. J Am Coll Cardiol. 2001;38:659–665
  38. Pache J, Kastrati A, Mehilli J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. 2003;41:1283–1288

 Dr Shishehbor is supported in part by the National Institutes of Health, National Institute of Child Health and Human Development, Multidisciplinary Clinical Research Career Development Programs grant K12 HD049091, and the National Institutes of Health Loan Repayment Program.

PII: S0002-8703(09)00614-0

doi: 10.1016/j.ahj.2009.08.003

American Heart Journal
Volume 158, Issue 4 , Pages 637-643 , October 2009

Article Tools

* Image Usage & Resolution